2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
M Aringer, K Costenbader, D Daikh… - Arthritis & …, 2019 - Wiley Online Library
Objective To develop new classification criteria for systemic lupus erythematosus (SLE)
jointly supported by the European League Against Rheumatism (EULAR) and the American …
jointly supported by the European League Against Rheumatism (EULAR) and the American …
Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts
C Díaz-Lagares, S Croca, S Sangle, EM Vital… - Autoimmunity …, 2012 - Elsevier
OBJECTIVE: To present a pooled analysis of the efficacy of rituximab from European cohorts
diagnosed with biopsy-proven lupus nephropathy (LN) who were treated with rituximab …
diagnosed with biopsy-proven lupus nephropathy (LN) who were treated with rituximab …
Emerging concepts of type I interferons in SLE pathogenesis and therapy
Type I interferons have been suspected for decades to have a crucial role in the
pathogenesis of systemic lupus erythematosus (SLE). Evidence has now overturned several …
pathogenesis of systemic lupus erythematosus (SLE). Evidence has now overturned several …
Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study
Objective: Primary Sjögren syndrome (pSS) causes significant systemic symptoms including
fatigue as well as glandular dysfunction. There are currently no effective systemic therapies; …
fatigue as well as glandular dysfunction. There are currently no effective systemic therapies; …
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
Background Type I interferons are involved in systemic lupus erythematosus (SLE)
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …
B cell biomarkers of rituximab responses in systemic lupus erythematosus
Objective Rituximab appears to be effective in many studies of systemic lupus
erythematosus (SLE), with variable initial clinical response and time to relapse. However …
erythematosus (SLE), with variable initial clinical response and time to relapse. However …
Development of psoriasis after B cell depletion with rituximab
The B cell–depleting monoclonal antibody rituximab is a novel therapy for the rheumatic
diseases, with an increasing body of evidence regarding its safety and efficacy in an …
diseases, with an increasing body of evidence regarding its safety and efficacy in an …
Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis
S Dass, AC Rawstron, EM Vital… - … : Official Journal of …, 2008 - Wiley Online Library
Objective In rheumatoid arthritis (RA), B cell depletion occurs in all patients treated with
rituximab, but the clinical responses to rituximab are variable. A highly sensitive assay was …
rituximab, but the clinical responses to rituximab are variable. A highly sensitive assay was …
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)
Background Baricitinib is an oral selective inhibitor of Janus kinase 1 and 2 approved for the
treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata. In a 24-week phase …
treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata. In a 24-week phase …
Effect of rituximab on the progression of rheumatoid arthritis–related interstitial lung disease: 10 years' experience at a single centre
MY Md Yusof, A Kabia, M Darby, G Lettieri… - …, 2017 - academic.oup.com
Objective. To evaluate the effect of rituximab (RTX) in patients with RA-related interstitial
lung disease (RA-ILD) and identify factors associated with outcome after treatment. Methods …
lung disease (RA-ILD) and identify factors associated with outcome after treatment. Methods …